Home
>
Stock Market
>
>
Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd share price and stock overview

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) operates in the Pharmaceuticals - Indian - Bulk Drugs & Formln sector. The stock has an ISIN of INE935A01035 and a face value of Rs 1. As of 28 October 2026, it trades at Rs (2,300.00) with a market capitalisation of Rs 64033.96 crore. Figures are live and subject to change.

Glenmark Pharmaceuticals Ltd

Pharmaceuticals - Indian - Bulk Drugs & Formln

NSE BSE

2,300.00 34.30 (1.51%) upARrowC

As on: 28-Oct-2026 , 04:27 PM

Market Cap(₹Cr) 64033.96

Book Value(₹Cr) 855.7128074

BSE Code : 532296 NSE Symbol : GLENMARK EPS(TTM) : 51.73 ISIN Demat : INE935A01035 P/E(TTM) : 43.86 Face Value(₹) : 1 Div & Yield % : 0.22

Today Market

Stock Performance

Today Market

Today's High

73,525.44

Todday's Low

72,603.57

Open at

73,253.44

Previous Close

73,598.67

Volumes

0.00

Avg Price

-352.64

Historical Performance

News

28 Oct 26

Glenmark Pharmaceuticals Ltd spurts 2.18%, rises for third straight session

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 2315, up 2.

28 Sep 26

Glenmark Pharmaceuticals restricts trading for insiders ahead of Q2 2026 results

Glenmark Pharmaceuticals Limited will close its trading window for designated persons, including directors, key managerial personnel, and immediate relatives, starting October 1, 2026, and continuing until the declaration of the company’s unaudited financial results for the second quarter ended September 30, 2026, and forty-eight hours thereafter.

22 Sep 26

Glenmark Pharmaceuticals Ltd gains for fifth session

Glenmark Pharmaceuticals Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 2462.

11 Sep 26

India Ratings affirmed Glenmark Pharmaceuticals' Bank Loans with an IND AA+ stable outlook

Glenmark Pharmaceuticals Ltd announced credit rating actions from India Ratings and Research, which affirmed its IND AA+ rating with a stable outlook for its Bank Loans and also rated Additional Loans, though specific details regarding the Additional Loans rating were not provided.

Historical Prices

Share Price Chart

Historical Share Price

Date	Open Price (₹)	High Price(₹)	Low Price(₹)	Close Price(₹)	Total Volume	No of Trades	Net Turnover(₹)	NIFTY
27-10-26	2214.70	2275.00	2214.60	2265.70	483378	34537	1088657713.30	22749.75
26-10-26	2135.60	2229.00	2133.00	2225.80	969672	46934	2129247943.00	22753.20
23-10-26	2196.00	2203.80	2101.60	2166.60	892797	51644	1905867328.50	22600.00
22-10-26	2168.00	2218.80	2160.30	2198.50	576619	36963	1266195590.50	22687.65
21-10-26	2216.00	2249.80	2163.10	2194.10	568717	37512	1248102797.30	22811.35
19-10-26	2230.10	2269.90	2200.00	2210.20	285702	21295	636518580.20	22888.95
16-10-26	2250.50	2266.90	2223.70	2226.70	695427	35858	1560390967.80	23146.15
15-10-26	2242.00	2289.50	2241.20	2250.50	488525	21801	1106185457.00	22997.35
14-10-26	2275.00	2286.40	2242.00	2246.00	257936	15947	582184373.50	22622.70
13-10-26	2278.00	2289.30	2253.00	2265.30	259977	14636	589144229.90	22721.95

12 3 ...

Fundamentals

Company Valuation

Market Cap (₹cr)

64033.96

PE Ratio

43.86

PB Ratio

2.65

Dividend Yield

0.22

ROE

3.87

ROCE

6.30

Book Value (₹)

855.7128074

Face Value (₹)

Share Holding Pattern

Category of Shareholder	No of Shares	% Share Holdings	Demat Shares	Share Holders

Promoter & Group

Foreign

Foreign (Promoter & Group) - Bodies Corporate	0	0.00	0	0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign)	0	0.00	0	0
Foreign Promoter(Institutional)	0	0.00	0	0
Promoter Others	0	0.00	0	0

Sub Total

0.00

Indian

Bodies Corporate-Indian (Promoter & Group)	0	0.00	0	0
Government(Central / State)-Indian (Promoter & Group)	0	0.00	0	0
Directors & their Relatives-Indian (Promoter & Group)	0	0.00	0	0
Financial Institutions / Banks-Indian (Promoter & Group)	0	0.00	0	0
Individuals / Hindu Undivided Family-Indian (Promoter & Group)	3415386	1.21	3415386	5
Partnership Firms-Indian (Promoter & Group)	0	0.00	0	0
Persons Acting in Concert	0	0.00	0	0
Trusts	128241936	45.44	128241936	1
Others	0	0.00	0	0

Sub Total

131657322

46.65

131657322

Total ShareHolding for Promoter & Group

131657322

46.65

131657322

Publice Share Holding

Institution

Government(Central / State)	107037	0.04	107037	3
Clearing Members	0	0.00	0	0
Corporate Bodies	0	0.00	0	0
Foreign Direct Investments	0	0.00	0	0
Financial Institutions / Banks	359371	0.13	359371	3
Foreign Bank	0	0.00	0	0
Foreign Bodies Corporate/OCBs/FBC	0	0.00	0	0
Foreign Collaborators	0	0.00	0	0
Foreign Institutional Investors	60699270	21.51	60699270	394
Foreign Venture Capital Investors	0	0.00	0	0
Foreign Institution Other	0	0.00	0	0
Insurance Companies	2373093	0.84	2373093	19
Mutual Funds / UTI	44067459	15.61	44067459	38
Individuals (Non-Resident / Foreign)	0	0.00	0	0
NSDL Intransit	0	0.00	0	0
Others	2971590	1.05	2971590	45
Trusts	0	0.00	0	0
Venture Capital Funds	0	0.00	0	0

Sub total

110577820

39.18

110577820

502

Non Institution

Bodies Corporate	7283744	2.58	7283744	1494
Clearing Members	22029	0.01	22029	5
Directors & their Relatives	23898	0.01	23898	1
Employees	0	0.00	0	0
Escrow Account	0	0.00	0	0
Foreign Corporate Bodies	0	0.00	0	0
Foreign Direct Investments	0	0.00	0	0
NRIs/Foreign Individuals/Foreign Nationals	2298997	0.81	2294997	6685
Foreign Non Institution Other	0	0.00	0	0
Hindu Undivided Families	517729	0.18	517729	3478
Indian Public	0	0.00	0	0
Individuals holding nominal share capital in excess of Rs. 1 lakh	6921148	2.45	6921148	12
Individuals holding nominal share capital up to Rs. 1 lakh	22536139	7.99	22330805	196211
Market Maker	0	0.00	0	0
NSDL Transit	0	0.00	0	0
Shares in transit	0	0.00	0	0
Societies	0	0.00	0	0
Trust & Foundation	99688	0.04	99688	17
Others	286158	0.10	286158	3

Sub Total

39989530

14.17

39780196

207906

Total Public Shareholding

150567350

53.35

150358016

208408

Total of Promoter & Public ShareHolding

282224672

100.00

282015338

208414

Shares held by Custodians and against which Depository Receipts have been issued

ADR	0	0.00	0	0
GDR	0	0.00	0	0
Other Custodians	0	0.00	0	0

Total Shares held by Custodians and against which Depository Receipts have been issued

0.00

Grand Total

282224672

100.00

282015338

208414

Financials (₹ in cr)

Consolidated Standalone

Year End	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Net Sales	16,982.51	13,321.74	11,813.10	11,583.24	12,304.90
OPM (%)	25.03	13.30	7.94	8.68	13.83
OP	4,250.83	1,772.03	937.45	1,005.70	1,702.16
Other Income	460.62	113.72	839.99	288.90	166.67
PBIDT	2,766.95	2,092.28	1,134.37	1,158.05	2,226.06
INTEREST	208.73	207.07	515.97	349.04	298.10
PBDT	2,558.23	1,885.22	618.40	809.02	1,927.96
PBT	-281.34	1,026.39	-864.46	-526.01	1,180.33
EO	-2,266.08	-372.82	-900.96	-765.85	-260.91
PBT after EO	1,984.75	1,399.21	36.50	239.84	1,441.25
TAXES	622.79	352.07	1,867.35	329.40	447.60
PAT	1,361.85	1,047.10	-1,501.67	297.25	941.71
EPS	48.24	37.11	-53.22	10.53	33.37
Raw Material	17.44	22.53	26.73	27.50	26.65
Power and Fuel	0.61	0.78	0.79	0.75	1.47
Employee Cost	21.07	22.69	24.28	22.45	19.89
Other Manufacturing Expenses	0.86	0.67	1.06	0.60	0.60
Selling and Administration Expenses	13.49	14.82	14.41	15.13	12.54
Miscellaneous Expenses	5.63	5.91	6.42	5.57	5.66
Revenue (Growth %)	27.48	12.77	1.98	-5.86	12.44
PBIDT (Growth %)	32.25	84.44	-2.04	-47.98	2.15
PAT (Growth %)	30.06	-169.73	-605.20	-68.44	-2.92
PBIDT (Margin %)	16.29	15.71	9.60	10.00	18.09
PAT (Margin %)	8.02	7.86	-12.71	2.57	7.65

Balance Sheet (₹ in cr)

Particulars (Sources Of Funds)	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Share Capital	28.22	28.22	28.22	28.22	28.22	28.22
Reserves Total	24122.10	24475.74	22942.40	17849.25	16710.37	14781.29
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	24150.32	24503.96	22970.62	17877.47	16738.59	14809.51
Secured Loans	0.00	298.82	0.00	0.00	0.00	0.00
Unsecured Loans	107.01	530.97	707.29	3221.22	3737.70	3703.99
Total Debt	107.01	829.79	707.29	3221.22	3737.70	3703.99
Other Liabilities	1591.09	132.10	131.94	372.58	121.32	136.61
Total Liabilities	25848.42	25465.85	23809.85	21471.27	20597.61	18650.11
APPLICATION OF FUNDS :
Gross Block	4015.83	3743.15	3392.75	3183.65	3026.28	2848.56
Less : Accumulated Depreciation	1987.93	1763.97	1636.50	1437.70	1273.95	1126.07
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	2027.90	1979.18	1756.25	1745.95	1752.33	1722.49
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	159.32	154.56	197.67	172.34	109.04	131.40
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	15202.21	15194.91	12964.79	10334.01	8559.39	6989.95
Current Assets, Loans & Advances
Inventories	1288.06	1369.31	1142.69	1090.21	951.66	762.39
Sundry Debtors	3305.59	2550.16	2484.47	2505.66	2678.32	2488.75
Cash and Bank Balance	293.19	132.74	129.15	93.79	29.63	15.79
Loans and Advances	1208.26	725.47	925.17	695.51	743.31	1642.20
Total Current Assets	6095.10	4777.68	4681.48	4385.18	4402.93	4909.12
Less : Current Liabilities and Provisions
Current Liabilities	3270.50	2383.39	3249.79	2952.14	2168.39	1834.31
Provisions	366.26	125.79	354.74	162.52	148.49	133.11
Total Current Liabilities & Provisions	3636.76	2509.18	3604.54	3114.66	2316.88	1967.41
Net Current Assets	2458.34	2268.50	1076.94	1270.52	2086.05	2941.71
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	968.61	166.59	475.61	1160.25	1137.47	1118.72
Deferred Tax Liability	962.57	224.85	309.77	213.50	214.20	265.43
Net Deferred Tax	6.04	-58.26	165.84	946.75	923.27	853.29
Other Assets	5994.61	5926.97	7648.37	7001.70	7167.54	6011.27
Total Assets	25848.42	25465.86	23809.85	21471.26	20597.62	18650.11
Contingent Liabilities	2590.04	2949.43	2658.49	3443.30	3325.06	3730.17

Cash Flow (₹ in cr)

Yearly Cash Flow	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Financing Activities	-305.12	-978.50	-2,666.45	-95.41	-952.13
Investing Activities	-897.02	-431.52	3,197.17	-489.90	569.21
Net Cash Flow	13.93	64.05	35.27	3.49	160.38
Operating Activities	1,216.07	1,474.06	-495.45	588.80	543.30

Peers

Balance Sheet Financial Ratios Profit & Loss

Aarti Pharmalabs...

881.95

(-0.45%)

Accent Microcell...

621.25

(-3.05%)

Accretion Pharma...

185.00

(0.00%)

Achyut Healthcar...

Advanced Enzyme ...

259.75

(-0.35%)

Akums Drugs & Ph...

722.70

(+0.48%)

Albert David Ltd

772.00

(-0.48%)

Alembic Pharmace...

782.80

(+2.07%)

Corporate Actions

Bonus Dividends Splits

Date	Corporate Action	Information
No Corporate Actions Announced

Board of Directors

Chairman & Chief Executive Officer

Glenn Saldanha

Chairman / Executive Director / M D / Promoter

Executive

Functional Directors

Cheryl Pinto

Executive Director (Corporate)

Exec.

Anurag Mantri

Executive Director & Group CFO

Exec.

BES

B E Saldanha

Non Executive Director

Exec.

Independent Directors

SSR

Sona Saira Ramasastry

Independent Non Exe. Director

Ind.

Dipankar Bhattacharjee

Independent Non Exe. Director

Ind.

VRI

V R Iyer

Independent Non Exe. Director

Ind.

PKS

Pradeep Kumar Sinha

Independent Non Exe. Director

Ind.

Patricia Andrews

Independent Non Exe. Director

Ind.

Company Secretary & Compliance

Rashmi Khandelwal.

Company Secretary / Compliance Officer

Sec.

Frequently Asked Questions

What is the NSE symbol and BSE code for Glenmark Pharmaceuticals Ltd? −

Glenmark Pharmaceuticals Ltd trades on NSE under GLENMARK and on BSE under code 532296. The ISIN is INE935A01035 and the face value is Rs 1.

What is the share price of Glenmark Pharmaceuticals Ltd today? +

As of 28 October 2026, Glenmark Pharmaceuticals Ltd trades at Rs 2,300.00, a change of 34.30 (1.51%) on the day. Prices are live and subject to change.

What is the market capitalisation of Glenmark Pharmaceuticals Ltd? +

As of 28 October 2026, Glenmark Pharmaceuticals Ltd has a market cap of about Rs 64033.96 crore. This figure is live and moves with the share price.

Is Glenmark Pharmaceuticals Ltd profitable? +

In March 2026, Glenmark Pharmaceuticals Ltd reported a profit after tax of Rs 1,361.85 crore. The wording switches to "a net loss of Rs X crore" when the figure is negative.

What is the PE ratio of Glenmark Pharmaceuticals Ltd? +

: As of 28 October 2026, the PE (TTM) for Glenmark Pharmaceuticals Ltd is 43.86 and the price-to-book ratio is 2.65. When the PE shows zero, state that PE TTM is currently not applicable and give the PB only.

Does Glenmark Pharmaceuticals Ltd pay a dividend? +

As of 28 October 2026, the dividend yield for Glenmark Pharmaceuticals Ltd is 0.22%. The wording switches to "does not currently pay a dividend" when the yield is zero.

What is the shareholding pattern of Glenmark Pharmaceuticals Ltd? +

As of the latest disclosed pattern, promoters hold 46.65% of Glenmark Pharmaceuticals Ltd. Public shareholding is 53.35%, including mutual funds at 15.61% and foreign institutional investors at 21.51%.

What were the latest annual financials of Glenmark Pharmaceuticals Ltd? +

In March 2026, Glenmark Pharmaceuticals Ltd reported net sales of Rs 16,982.51 crore, revenue growth of 27.48%, and earnings per share of Rs 48.24.